How the ubiquitously-expressed SMN-1 protein is required in a single tissue to avoid degenerative defects caused by hyperactive proteasome activity is revealed, contributing to the understanding of how mutations in ubiquitously-expressed genes can cause highly cell-specific pathologies.
Abstract
Many neurological diseases are caused by mutations in broadly-expressed genes, but the basis for their neuron-specific manifestation is unclear. In Spinal Muscular Atrophy (SMA), loss of the ubiquitously-expressed spliceosome assembly factor SMN1 causes selective degeneration of motor neurons, leading to progressive neuromuscular decline. We explored the mechanisms of this cell-specific vulnerability using SMA models in the nematode C. elegans, which likewise exhibit progressive neuromuscular defects upon loss of smn-1. Surprisingly, our results show that the intestine – not neurons or muscle – is the selectively-vulnerable tissue causing smn-1 phenotypes. RNA-Seq reveals that loss of intestinal smn-1 causes specific global splicing defects, accompanied by robust transcriptional activation of the Intracellular Pathogen Response (IPR), a stress pathway enriched for ubiquitin-proteostasis genes. Consistent with this, smn-1 mutants exhibit elevated levels of proteasome activity. Pharmacological proteasome inhibition rescues many of the smn-1 mutant defects, as does deletion of specific components of the IPR pathway. These results reveal how the ubiquitously-expressed SMN-1 protein is required in a single tissue to avoid degenerative defects caused by hyperactive proteasome activity, contributing to our understanding of how mutations in ubiquitously-expressed genes can cause highly cell-specific pathologies. SIGNIFICANCE STATEMENT Many ubiquitously expressed genes cause highly selective neurodegenerative diseases, such as Huntington’s disease and Amyotrophic Lateral Sclerosis. The basis for this cell-specific vulnerability remains unclear. We address this question for smn-1 in C. elegans. We show that smn-1 is indeed required in a cell-specific manner, but unexpectedly not in neurons, but rather in the intestine. Both survival defects and behavioral phenotypes originate from intestinal loss of smn-1. We show that these defects are caused by hyperactive protein degradation and immune responses, and that mutant defects can be resolved by reducing these proteostasis and immune pathways using genetics or pharmacology. These results shed light on how a single tissue/cell can dictate the effects of a systemic genetic disease.
Findings support enhancing autophagic activity as a combinatorial treatment strategy for SMA patients by identifying that pharmacological activation of autophagy, but not inhibition, significantly improved neuromuscular function, as indicated by two independent functional readouts.
Saman Rashid, Coral Crespo Gómez, Maria Dimitriadi· ACS Chemical Neuroscience· 0 citations
Hundreds of mutations to the broadly expressed LMNA gene cause disease primarily within cardiac, muscular, and adipose tissues1. Tissue-specific pathogenesis arises when mutant protein dysfunction collides with the unique demands of a specific cell type. Here, we decipher the cell-type-specific consequences of ∼15,000...
Jessica Mella, Abigail E. Hein, Navraj Lally et al.· bioRxiv· 0 citations
It is demonstrated that tmlhe deficiency disrupts carnitine biosynthesis, impairing energy and glycerophospholipid metabolism, which is critical for early neurogenesis, which may lead to impaired neural development and a synaptic E/I imbalance, ultimately causing ASD-like phenotypes.
Ji-Tong Li, Xiao-Tong Zhao, Jie-Ru Wei et al.· Progress in Neuro-psychophar...· 0 citations
Proteasomal inhibitors, drugs already approved for treatment of patients with multiple myeloma, warrant further studies to prevent renal failure in patients with nail-patella syndrome caused by mutations in the LIM domains, providing proof of principle for a novel therapeutic strategy.
Joshua Hermens, Lisa Lucke, O. Pieles et al.· Nature Communications· 0 citations
The RUBCN-related disorders are established and expand as a clinically and molecularly distinct subset of autophagy-related diseases and enhances understanding of autophagy-related neurodevelopmental disorders and provides a foundation for future therapeutic investigations.
S. Efthymiou, K. Tabata, H. Dafsari et al.· medRxiv· 0 citations
This review examines the regulatory mechanisms that control SMN protein stability, collectively termed proteostasis, with a focus on how post-translational modifications coordinate with the ubiquitin-proteasome system and the autophagy-lysosomal pathway to govern protein turnover and clearance.
Bradley R. Smith, Rachel Massalee, Mason Mayer et al.· Frontiers in Cellular Neuros...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.